Vienna residents awaiting their second shingles vaccination face ongoing supply shortages, leaving thousands of patients in limbo.
Since the government integrated the vaccine into the free immunization program for high-risk individuals and those over 60 one year ago, 71,000 residents have received their initial dose, according to wien.orf.at.
The virus behind shingles is the same pathogen that causes chickenpox. Once a person has contracted chickenpox, the virus persists in the body and can reactivate years later in one out of every three people, said dermatologist Rainer Kunstfeld, according to Orf.
Shingles Vaccine Shortages Force Difficult Clinical Decisions
While shingles can erupt across the skin, it most frequently surfaces on the abdomen. Outbreaks on the head and neck are particularly concerning due to the risk of serious complications, Kunstfeld said.
The Vienna Medical Chamber has criticized the chronic shortages, as the vaccine is frequently sold out. Rainer Wolschner, a consultant for vaccination affairs at the chamber, reported that some physicians have patients who have been waiting almost a year for their second dose.
Practitioners are now forced to make difficult clinical decisions regarding their limited inventory. Wolschner said:
“From colleagues, I have heard that patients are now waiting almost a year for the second vaccination, and that is also the discrepancy: Are colleagues now waiting for the patient who is supposed to receive the second vaccination in eight weeks? Or are they trying to give as many first vaccinations as possible?”
Despite the delays, medical experts maintain that patients waiting for their second injection remain protected. “The first partial vaccination already protects against shingles,” Kunstfeld said. While the second dose is necessary for long-term immunity, studies indicate that the vaccine’s efficacy remains comparable even if the booster is administered after one year.
Physicians are currently unable to order new supplies through the health ministry’s platform. Although officials informed wien.orf.at that new stocks would be available next week, most doses are not expected to reach medical practices until January.